Fortress Biotech Inc (FBIO) was Initiated by ROTH Capital to “Buy” and the brokerage firm has set the Price Target at $9. ROTH Capital advised their investors in a research report released on Oct 3, 2016.
Fortress Biotech Inc opened for trading at $2.87 and hit $2.99 on the upside on Friday, eventually ending the session at $2.97, with a gain of 4.21% or 0.12 points. The heightened volatility saw the trading volume jump to 58,594 shares. Company has a market cap of $145 M.
In a different news, on Sep 19, 2016, George Avgerinos (SVP, Biologics Operations) sold 48,912 shares at $2.55 per share price. According to the SEC, on Jun 17, 2016, Lindsay A Md Rosenwald (CEO) purchased 613 shares at $2.40 per share price.
Fortress Biotech Inc. formerly Coronado Biosciences Inc. is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer namely CNDO-201 or Trichuris suis ova (TSO) and CNDO-109. As of December 31 2014 TSO the microscopic eggs of the porcine whipworm was in Phase II study stage for the treatment of immune-mediated diseases such as Crohn’s disease (CD) ulcerative colitis (UC) or autism spectrum disorder (ASD). The Company’s CNDO-109 is a biologic that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells and as of December 31 2014 was in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML). The Company’s subsidiary Journey Medical Corporation (JMC) focuses on acquiring developing licensing and commercializing branded dermatology products.